BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sapacitabine: Phase II data

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J.
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Product: Sapacitabine ( CYC682)...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >